DCEP regimen
WikiDoc Resources for DCEP regimen |
Articles |
---|
Most recent articles on DCEP regimen Most cited articles on DCEP regimen |
Media |
Powerpoint slides on DCEP regimen |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on DCEP regimen at Clinical Trials.gov Clinical Trials on DCEP regimen at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on DCEP regimen
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on DCEP regimen Discussion groups on DCEP regimen Patient Handouts on DCEP regimen Directions to Hospitals Treating DCEP regimen Risk calculators and risk factors for DCEP regimen
|
Healthcare Provider Resources |
Causes & Risk Factors for DCEP regimen |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Overview
DCEP regimen refers to a regimen consisting of Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients.[1]
Regimen
DDexamethasone
CCyclophosphamide
EEtoposide
PCisplatin
Indications
- Relapsed or refractory multiple myeloma[1]
References
- ↑ 1.0 1.1 Dadacaridou M, Papanicolaou X, Maltesas D, Megalakaki C, Patos P, Panteli K; et al. (2007). "Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients". J BUON. 12 (1): 41–4. PMID 17436400.